YRNA expression predicts survival in bladder cancer patients

Tolkach, Yuri; Stahl, Anna Franziska; Niehoff, Eva-Maria; Zhao, Chenming; Kristiansen, Glen; Müller, Stefan; Ellinger, Jörg

doi:10.1186/s12885-017-3746-y

Cited by 20 publications

(43 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No additional studies were identified by a manual search of the references of the original studies. Finally, the remaining 37 articles were eligible for the systematic review (Wang et al, 2006 ; He et al, 2013 , 2016a , b ; Fan et al, 2014 ; Li et al, 2014 , 2017 ; Srivastava et al, 2014 ; Yan et al, 2014 ; Chen et al, 2015 , 2017 ; Eissa et al, 2015a , b ; Milowich et al, 2015 ; Zhao F. J. et al, 2015 ; Zhao X. L. et al, 2015 ; Duan et al, 2016 ; Iliev et al, 2016 ; Zhan et al, 2016a , b , 2017a , b ; Zhang et al, 2016 , 2017 ; Cao et al, 2017 ; Cui et al, 2017 ; Dudek et al, 2017 ; Du et al, 2017 ; Hu Y. Y. et al, 2017 ; Liao et al, 2017 ; Lin et al, 2017 ; Tolkach et al, 2017 ; Wu et al, 2017 ; Xiong et al, 2017 ; Yang et al, 2017 ; Ye et al, 2017 ; Zhuang et al, 2017 ), including 26 studies for clinicopathological parameters, 19 studies for prognosis, and 7 studies for diagnosis.…”

Section: Resultsmentioning

confidence: 99%

“…Conversely, an observed HR > 1 implied that the patients with increased lncRNAs expression had a worse survival. Increased expressions of MALAT1 (Fan et al, 2014 ; Li et al, 2017 ), ASAP1-IT1 (Yang et al, 2017 ), SPRY4-IT1 (Zhao X. L. et al, 2015 ), TUG1 (Iliev et al, 2016 ), lncRNA-n336928 (Chen et al, 2015 ), GHET1 (Li et al, 2014 ), linc-UBC1 (He et al, 2013 ), YRNA5 (Tolkach et al, 2017 ), XIST (Hu Y. Y. et al, 2017 ), PVT1 (Cui et al, 2017 ), and SNHG16 (Cao et al, 2017 ) were significantly correlated with poor prognosis in OS, along with decreased expressions of CAT1297 (Dudek et al, 2017 ), lncRNA-LET, YRNA1 (Tolkach et al, 2017 ), YRNA3 (Tolkach et al, 2017 ), YRNA4 (Tolkach et al, 2017 ), and NBAT1 (Du et al, 2017 ). It was worth noting that the most significant association was observed between increased expressions of SPRY4-IT1 and poor OS (HR = 3.716; 95% CI: 2.084–6.719; p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

“…One study containing 4 lncRNAs were available to evaluate the relationship between abnormally expressed lncRNAs and CSS of bladder cancer patients. Increased expressions of YRNA4 (Tolkach et al, 2017 ) and YRNA5 (Tolkach et al, 2017 ) were significantly correlated with poor prognosis in CSS, along with decreased expressions of YRNA1 (Tolkach et al, 2017 ) and YRNA3 (Tolkach et al, 2017 ). Three studies containing 3 lncRNAs were available to evaluate the relationship between abnormally expressed lncRNAs and RFS of bladder cancer patients.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

Wang

2018

Front. Physiol.

View full text Add to dashboard Cite

Background: Increasing evidence shows that dysregulated expression of long non-coding RNAs (lncRNAs) can serve as diagnostic or prognostic markers in bladder cancer. The aim of this study was to evaluate the clinical values of dysregulated lncRNAs in bladder cancer.Methods: Eligible studies were systematically searched in PubMed, Embase, and Web of Science databases from inception to December 2017. Odds ratios (OR) were calculated to investigate the correlation between lncRNAs and clinicopathological parameters. Pooled hazard ratios (HR) and 95% confidence interval (CI) were calculated to explore the prognostic value of lncRNAs in bladder cancer. Pooled diagnostic parameters were also calculated to estimate the performance of lncRNAs in diagnosing bladder cancer. All statistical analyses were performed by using STATA 13.1 program.Results: A total of 37 relevant studies were included to the present systematic review according to the inclusion and exclusion criteria, including 26 on clinicopathological parameters, 19 on prognosis, and 7 on diagnosis. For clinicopathological parameters, MALAT1 expression was significantly associated with lymph node metastasis (OR = 2.731; 95% CI: 1.409–5.292; p = 0.003), and high-level expression of XIST was related to larger tumor size (OR = 2.473; 95% CI: 1.159–5.276; p = 0.019) and higher TNM stage (OR = 0.400; 95% CI, 0.184–0.868; p = 0.020). For the prognostic values, the most significant association was observed between increased expressions of SPRY4-IT1 and poor overall survival (OS) (HR = 3.716; 95% CI: 2.084–6.719; p < 0.001); high MALAT1 expression was significantly associated with poor OS (HR = 1.611; 95% CI: 1.076–2.412; p = 0.020). For the diagnostic values, UCA1 expression profile achieved a combined AUC of 0.92, with sensitivity of 0.84 and specificity of 0.89 in distinguishing patients with bladder cancer from non-cancerous controls.Conclusions: In summary, systematic review elaborated that abnormal lncRNAs expression can serve as potential markers for prognostic evaluation in bladder cancer patients. In addition, the diagnostic meta-analysis concluded that abnormally expressed UCA1 can function as potential diagnostic markers for bladder cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

Wang

2018

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…To verify if full-length RNY4 might be responsible for the differential expression detected by small RNA-seq, not validated by RT-PCR specific from RNY4-5 ′ F, we quantified the full-length RNY4 in 12 ALCL and 12 HD plasmatic exosomes by qRT-PCR using primers from Tolkach et al (63). The full-length RNY4 was significantly more abundant in ALCL than in HD (Mann Whitney, p = 0.017) (Figure 2A).…”

Section: Genuine Mirna-like Rny4 Fragments or Full-length Rny4?mentioning

confidence: 99%

RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player?

et al. 2020

View full text Add to dashboard Cite

Emerging evidence indicates that extracellular vesicles, particularly exosomes, play a role in several biological processes and actively contribute to cancer development and progression, by carrying and delivering proteins, transcripts and small RNAs (sRNAs). There is high interest in studying exosomes of cancer patients both to develop non-invasive liquid biopsy tests for risk stratification and to elucidate their possible involvement in disease mechanisms. We profiled by RNA-seq the sRNA content of circulating exosomes of 20 pediatric patients with Anaplastic Large Cell Lymphoma (ALCL) and five healthy controls. Our analysis disclosed that non-miRNA derived sRNAs constitute the prominent fraction of sRNA loaded in exosomes and identified 180 sRNAs significantly more abundant in exosomes of ALCL patients compared to controls. YRNA fragments, accounting for most of exosomal content and being significantly increased in ALCL patients, were prioritized for further investigation by qRT-PCR. Quantification of RNY4 fragments and full-length sequences disclosed that the latter are massively loaded into exosomes of ALCL patients with more advanced and aggressive disease. These results are discussed in light of recent findings on the role of RNY4 in the modulation of tumor microenvironment.

show abstract

“…YRNAs are recognized as a component of soluble ribonucleoproteins (RNPS). These are related with many pathological conditions [ 100 ]. The Ro60 protein bound to the YRNAs controls the fate of the misfolded RNAs.…”

Section: Yrnasmentioning

confidence: 99%

The Unforeseen Non-Coding RNAs in Head and Neck Cancer

Irimie

Zimța

Ciocan

et al. 2018

Genes

View full text Add to dashboard Cite

Previously ignored non-coding RNAs (ncRNAs) have become the subject of many studies. However, there is an imbalance in the amount of consideration that ncRNAs are receiving. Some transcripts such as microRNAs (miRNAs) or small interfering RNAs (siRNAs) have gained much attention, but it is necessary to investigate other “pieces of the RNA puzzle”. These can offer a more complete view over normal and pathological cell behavior. The other ncRNA species are less studied, either due to their recent discovery, such as stable intronic sequence RNA (sisRNA), YRNA, miRNA-offset RNAs (moRNA), telomerase RNA component (TERC), natural antisense transcript (NAT), transcribed ultraconserved regions (T-UCR), and pseudogene transcript, or because they are still largely seen as non-coding transcripts with no relevance to pathogenesis. Moreover, some are still considered housekeeping RNAs, for instance small nucleolar RNAs (snoRNAs) and TERC. Our review summarizes the biogenesis, mechanism of action and potential role of less known ncRNAs in head and neck cancer, with a particular focus on the installment and progress for this particular cancer type.

show abstract

YRNA expression predicts survival in bladder cancer patients

Cited by 20 publications

References 26 publications

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player?

The Unforeseen Non-Coding RNAs in Head and Neck Cancer

Contact Info

Product

Resources

About